ISTA
Pharmaceuticals, Inc. (Nasdaq: ISTA), announced positive results from
the preliminary analysis of its second and final Bepreve(TM) (bepotastine
ophthalmic solution) Phase III clinical study. The U.S. multi-center
conjunctival allergen challenge (CAC) study evaluated the onset and
duration of effect of two Bepreve concentrations in 130 patients with a
history of ocular allergies. Both concentrations demonstrated highly
statistically significant Read the rest of this entry »
Men’s Health News
Older men who take loop diuretics, commonly prescribed drugs for heart failure and hypertension, appear to have increased rates of hip bone loss than men who are not taking this medication, according to a report in the April 14 issue of Archives of Internal Medicine.
"Loop diuretics are one of the most commonly Read the rest of this entry »
AstraZeneca announced a European decentralized procedure (DCP) submission seeking approval for two new dose strengths of Atacand Plus, for those hypertensive patients not optimally controlled by monotherapy. The reference member state for the procedure is Sweden, and the submission incorporates data from three studies. Read the rest of this entry »
People who suffer from severe depression following a heart attack might be more likely to experience cardiac complications while hospitalized, according to a new study.
"There is good evidence that if a person has depression after a heart attack, they are more likely to die from cardiac causes in the following Read the rest of this entry »
Some form of immunotherapy is expected to be available for peanut allergy within the next five years. But the reasons for the increasing prevalence of this allergic reaction remain unclear. The issues are discussed by Professor Wesley Burks, Duke University Medical Center, NC, USA, in a Seminar in this week’s edition of The Lancet.
Peanut allergy has become a major health concern worldwide, especially in developed countries, and affects around Read the rest of this entry »